Newsroom

Sorted by: Latest
-

Arverne Group : Une année 2025 exceptionnelle, marquée par des avancées majeures

PAU, France--(BUSINESS WIRE)--Regulatory News: Arverne (FR001400JWR8 - ARVEN), 1er fournisseur français de solutions géothermales, annonce ses résultats annuels 2025. Pierre Brossollet, fondateur et Président Directeur Général d’Arverne, déclare : « Porté par un engagement collectif en faveur de la souveraineté énergétique française et européenne, à travers le développement de la chaleur et du lithium géothermals, Arverne crée une valeur durable au service des territoires et de la transition én...
-

Arverne Group: An Exceptional Year in 2025, Marked by Major Milestones

PAU, France--(BUSINESS WIRE)--Regulatory News: Arverne (FR001400JWR8 – ARVEN), France’s leading provider of geothermal solutions, announces its 2025 annual results. Pierre Brossollet, Founder and Chief Executive Officer of Arverne, commented: “Driven by a collective commitment to French and European energy sovereignty, through the development of geothermal heat and geothermal lithium, Arverne is creating sustainable value in support of local communities and the energy transition. In 2025, the G...
-

BlackRock TCP Capital Corp. Investor Alert - TCPC Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired BlackRock TCP Capital Corp. (NASDAQ: TCPC) securities between November 6, 2024 and January 23, 2026. BlackRock TCP is a business development company that raises funds from investors and then uses those funds to make loans to small and midsize businesses as an alternative to bank financing. For more information, submit a form, email attorney Aa...
-

MREO Investor Alert - Mereo BioPharma Group plc Investors with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Mereo BioPharma Group plc. (NASDAQ: MREO) American Depository Shares ("ADS") between June 5, 2023 and December 26, 2025. Mereo is a biopharmaceutical company focused on the development of therapeutics for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the alleg...
-

HTGC Investors Have Opportunity to Lead Hercules Capital, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--HTGC Investors Have Opportunity to Lead Hercules Capital, Inc. Securities Fraud Lawsuit with the Schall Law Firm...
-

Oceaneering Schedules First Quarter 2026 Earnings Release and Conference Call

HOUSTON--(BUSINESS WIRE)--Oceaneering Schedules First Quarter 2026 Earnings Release and Conference Call: April 22 and April 23, respectively....
-

Pembina Pipeline Declares Quarterly Preferred Share Dividends and Announces Business Update and First Quarter 2026 Results Conference Calls

CALGARY, Alberta--(BUSINESS WIRE)--Pembina Pipeline Corporation ("Pembina" or the "Company") (TSX: PPL; NYSE: PBA) announced today that its Board of Directors has declared quarterly dividends for the Company's preferred shares, Series 1, 3, 5, 7, 15, 17, 21 and 25. Series 1, 3, 5, 7, and 21 preferred share dividends are payable on June 1, 2026, to shareholders of record on May 1, 2026. Series 15 and 17 preferred share dividends are payable on June 30, 2026, to shareholders of record on June 15,...
-

Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the "Company"), announces that it has signed, on March 25, 2026, the new Tranche D PDR subscription agreement with IPF Partners ("IPF"), for €3.75 million as part of th...
-

Poxel confirme la mise à disposition de l’emprunt obligataire complémentaire Tranche D PDR dans le cadre du plan de continuation

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), une entreprise biopharmaceutique en phase clinique qui a développé des traitements innovants pour des maladies chroniques graves à pathophysiologie métabolique, notamment la stéatohépatite associée au dysfonctionnement métabolique (MASH) et les maladies métaboliques rares (la « Société »), annonce avoir signé le 25 mars 2026 le nouvel accord de souscription Tranche D PDR avec IPF Partners (« IPF »), pour...
-

Riassunto: ECU Worldwide presenta l'espansione di XLERATE 2.0 per evitare le interruzioni nella catena di fornitura tra Europa e Asia

BRUXELLES--(BUSINESS WIRE)--ECU Worldwide, l'azienda globale interamente controllata di Allcargo Globals, ha annunciato un'espansione strategica della sua soluzione logistica innovativa, XLERATE 2.0, per fornire un'alternativa rapida e resiliente alle rotte commerciali tra Europa e Asia, che stanno subendo interruzioni nel transito. Questo percorso alternativo prevede il trasporto di merci attraverso l'Oceano Pacifico alla West Coast statunitense, utilizzando Los Angeles (LAX) come polo tempora...